XRF Scientific Limited (ASX:XRF): What FY27 Equipment Demand Reveals After Record FY26 Sales

Aditi Sarkar

11 November 2026 04:49 PM AEDT

XRF Scientific Limited (ASX:XRF): What FY27 Equipment Demand Reveals After Record FY26 Sales

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 Revenue increased 8% to AUD 64.4 million, while net profit reached AUD 10.5 million.
September 2026 quarter revenue reached AUD 21.1 million, up 38% year on year.
The company reported stronger Orbis crusher Demand and consumables activity.
New CGA instruments and international operations remain FY27 execution priorities.

XRF Scientific Limited (ASX:XRF) manufactures equipment, chemicals and consumables used in sample preparation and analysis by mining, Manufacturing and commercial laboratory customers. Its operations span Capital equipment, precious metals and consumable products. FY26 delivered higher revenue and modest statutory profit growth, while the September 2026 trading update indicated stronger demand across multiple divisions as the company integrates newly acquired product capabilities.

FY26 Financial Performance and Profitability

For the year ended 30 June 2026, XRF Scientific Limited (ASX:XRF) reported revenue of AUD 64.4 million, an 8% increase from approximately AUD 59.4 million in FY25. Statutory profit before tax rose 5% to AUD 15.4 million, while net profit attributable to members was AUD 10.5 million, approximately 1% higher. Profit growth therefore lagged revenue growth on a statutory basis.

Adjusted profit before tax was AUD 16.1 million, up 10%, excluding about AUD 0.69 million of Acquisition and international office start-up costs. This adjusted measure provides additional operating context but does not replace the statutory result. Operating cash inflow was AUD 11.4 million. The company also declared a final fully Franked Dividend of 4.5 cents per share.

Capital Equipment and Product Portfolio

XRF Scientific Limited (ASX:XRF) supplies sample preparation systems, including Orbis crushing equipment, as well as analytical instruments and related materials. In FY26, capital equipment revenue increased, supported by orders from Mining and commercial laboratory customers. The wider product mix is intended to serve workflows requiring reliable preparation and measurement of material samples.

The company acquired the CGA elemental analysis instrument Business in 2026. Integrating the product line into Perth manufacturing adds a route to future sales but also requires operational transition and customer support. Management has outlined new product development alongside international expansion, both of which involve expenditure before the full revenue contribution can be established.

September Quarter Extends Trading Growth

In the quarter ended 30 September 2026, XRF Scientific Limited (ASX:XRF) reported unaudited revenue of AUD 21.1 million, up 38% from AUD 15.3 million a year earlier. Profit before tax reached AUD 4.4 million, a 30% increase from AUD 3.4 million. These quarterly results are not directly comparable with audited full-year figures without considering seasonality and reporting scope.

Consumables sales were AUD 5.6 million versus AUD 4.4 million in the corresponding quarter. Capital equipment sales reached AUD 5.9 million against AUD 5.0 million, with Orbis revenue rising 66% to AUD 2.4 million. The company also launched two Orbis products during the period. Demand across several product categories gives substance to the quarterly improvement rather than relying on one equipment line.

CGA Integration, Markets and Risks

XRF Scientific Limited (ASX:XRF) said its Indian office was profitable during the September quarter and expected the December 2026 quarter to benefit from CGA instruments and Orbis activity. Those expectations are forward-looking and may change with production readiness, order conversion or customer timing. The company continues to serve mining and industrial markets whose spending can be uneven.

New product introductions require manufacturing, distribution and technical support, while precious metals activities may experience shifts in demand and input costs. The September results offer evidence of stronger early-FY27 trading, but maintaining that pace across subsequent quarters will require further execution. Monitoring order intake, margins and Cash Flow alongside revenue is therefore appropriate.

Key Insights

XRF Scientific Limited (ASX:XRF) followed FY26 revenue growth with a stronger September 2026 trading quarter. Capital equipment, consumables and CGA integration are key operating themes, while customer demand and delivery remain the principal uncertainties.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.